Here's How Much Eli Lilly Stock Is Expected to Move After Earnings

Options pricing implies Eli Lilly shares could move about 5% in either direction by the end of the week after Thursday’s Q3 report, with a potential range of roughly $1,215 to $1,349 from Tuesday’s close. Analysts expect revenue of $22.61 billion, up about 28% year over year, and adjusted EPS of $6.25 versus $7.02 a year earlier; Mounjaro and Zepbound sales are forecast to rise 54% and 40%, respectively. Investors will also assess guidance amid high expectations, while Foundayo sales are projected at $231.77 million, up from $98 million in the prior quarter.

Analysis

The setup is less about whether demand remains strong than whether incremental growth can still clear a high bar. With optimism concentrated in obesity products, a headline beat without stronger forward guidance, evidence of adequate supply, and confirmation of realized net pricing could be treated as a sell-the-news event. Revenue growth alongside lower expected year-over-year adjusted EPS also makes the quality and conversion of sales into earnings important; verify product mix, pricing, and launch/investment costs rather than extrapolating revenue alone.

Near term, the options-implied move is a hurdle, not a forecast: buying premium only works if the realized move exceeds what is priced, while a guidance-driven gap makes naked short volatility dangerous. The contrarian risk is that the market is underwriting a durable obesity franchise while giving insufficient weight to access/pricing pressure, supply expansion by competitors such as Novo Nordisk, or slower conversion of oral-drug interest into repeat prescriptions. These are medium-term risks, not evidence that demand has already rolled over. Over 6–18 months, capacity, payer access, and net price matter more than one quarter’s sales growth. The article provides no independent evidence on these measures; verify them in the release and call.

Key Decisions for Investors

• Avoid initiating a large outright LLY position immediately ahead of earnings: the event is binary and a strong print may already be reflected in expectations. Reassess after the release against guidance, net pricing, supply commentary, and earnings conversion.
• If guidance and those operating indicators confirm continued growth, consider scaling into LLY on a post-print pullback; use a defined-risk call spread rather than paying uncapped event premium. Invalidate the bullish setup on weaker forward guidance, deteriorating pricing/access, or evidence that supply is limiting sales rather than supporting future growth.
• If results meet estimates but guidance fails to raise the forward trajectory, avoid chasing the initial move and consider reducing exposure; a disappointment can produce a sharp reversal after recent strength. Do not short solely on a routine miss without checking whether the long-term demand and supply outlook changed.
• Treat any short-volatility trade as a watch item, not a recommendation, until current implied volatility is compared with LLY’s historical post-earnings moves and the relevant expiration. The thesis is falsified if the realized move is consistently below the priced move without adverse guidance; a large guidance-driven gap is the principal risk to short premium.